secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2022-07-01T23:59:59+00:00
Accession:  0001213900-22-036694
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Therapeutics CFO/COO steps down; Jillian Thomsen named CFO; CCO separation detailed
--------------------------------------------------------------------------------

- Gil Labrucherie steps down as CFO and COO effective July 1, 2022.
- Jillian Thomsen promoted from SVP Finance and CAO to SVP and CFO effective July 1, 2022.
- John Northcott, SVP and CCO, separated June 30, 2022; receives $921,206 lump sum severance.
- Northcott gets consulting retainer of $20k/month for up to 60 hours, $335/hr thereafter through Dec 31, 2022.
- Vested options for Northcott remain exercisable until June 30, 2023; no further vesting of unvested awards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390022036694/0001213900-22-036694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390022036694/ea162348-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-036694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer